Explore 3 Stock Ideas & Industry Insights Download Free Report
AstraZeneca published its results for the nine months and third quarter of 2026 on the London Stock Exchange. Third-quarter total revenue was USD 16,209m, up 7% on both a reported basis and at constant exchange rates (CER). Product sales rose 5% to USD 15,066m, …
HUTCHMED (China) Limited, which is quoted on AIM andNasdaqunder LSE:HCM and in Hong Kong under 13, announced on 29 October 2026 that the US FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia, or ITP.
The FTSE 100 more than reversed Monday's advance on Tuesday, ending the session close to 1% lower. Heavy falls in HSBC Holdings (LSE:HSBA) and Reckitt Benckiser (LSE:RKT) weighed on the index, while investors stayed cautious ahead of the UK Autumn Budget on Wednesday and …
IXICO plc, the AIM-quoted neuroscience imaging and biomarker analytics company, said on 29 October 2026 that it had presented new research at the European Huntington's Disease Network (EHDN) Clinical Research Congress 2026. The release was issued through a non-regulatory press release service, rather than …
Feedback plc, the AIM-quoted clinical infrastructure specialist with LSE:FDBK, published aBusinessupdate on 29 October 2026. The company said the announcement contained inside information under UK market abuse rules.
Convatec Group Plc — LSE:CTEC closed 0.82% higher on 30 October 2026, with the shares at 245.2p after an increase of 2.00p on the day.
Gsk Plc — LSE:GSK closed 2.48% higher on 30 October 2026, with the shares at 1,859.0p after an increase of 45.00p on the day.
Haleon Plc — LSE:HLN closed 1.83% higher on 30 October 2026, with the shares at 323.5p after an increase of 5.80p on the day.
Astrazeneca Plc — LSE:AZN closed 0.24% higher on 30 October 2026, with the shares at 102.625p after an increase of 0.25p on the day.
The centralInvestmentdebate combines clinical or commercial progress and funding visibility with the practical constraints of regulatory uncertainty, trial execution, commercial adoption and financing.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…